Axitinib
ATC Code
L01EK01
Axitinib
Definition
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.
Also known as AG 013736, AG-013736, AG013736, AXITINIB, Inlyta, N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide — per NCIT
Also identified as
- ATC L01EK01 per RXNORM
- NCIT NCIT:C38718 per NCIT
- SCTID 427882000 per RXNORM
- SCTID 429507005 per RXNORM
- UNII C9LVQ0YUXG per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Renal cell carcinoma | may treat | MEDRT · Public domain (U.S. Government work) |